在一项前瞻性多中心队列研究中,使用原始或管家归一化的 miR-371a-3p 血清水平,在主动监测期间检测 I 期睾丸生殖细胞肿瘤男性患者复发的临界值。

Christian D. Fankhauser M.D. , Marian S. Wettstein M.D., Ph.D. , Ailsa J. Christiansen M.D., Ph.D. , Christian Rothermundt M.D., PD , Richard Cathomas M.D. , Ernest Kaufmann M.D. , Silvan Sigg M.D. , Arnoud J. Templeton M.D. , Anita Hirschi-Blickenstorfer M.D. , Anja Lorch M.D. , Silke Gillessen M.D. , Joerg Beyer M.D. , Thomas Hermanns M.D., PD
{"title":"在一项前瞻性多中心队列研究中,使用原始或管家归一化的 miR-371a-3p 血清水平,在主动监测期间检测 I 期睾丸生殖细胞肿瘤男性患者复发的临界值。","authors":"Christian D. Fankhauser M.D. ,&nbsp;Marian S. Wettstein M.D., Ph.D. ,&nbsp;Ailsa J. Christiansen M.D., Ph.D. ,&nbsp;Christian Rothermundt M.D., PD ,&nbsp;Richard Cathomas M.D. ,&nbsp;Ernest Kaufmann M.D. ,&nbsp;Silvan Sigg M.D. ,&nbsp;Arnoud J. Templeton M.D. ,&nbsp;Anita Hirschi-Blickenstorfer M.D. ,&nbsp;Anja Lorch M.D. ,&nbsp;Silke Gillessen M.D. ,&nbsp;Joerg Beyer M.D. ,&nbsp;Thomas Hermanns M.D., PD","doi":"10.1016/j.urolonc.2024.07.013","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>MiR-371a-3p represents a novel liquid biomarker that detects all histologies of germ-cell tumors (GCT) except teratoma. However, it is currently unclear whether miR-371a-3p results obtained directly from RT-PCR (raw Cq) or normalized for housekeeper genes and transformed into the relative quantity (RQ) value should be used and at what cut-off level. The purpose of this research was to evaluate, which values should be used, and a potential cut-off level for relapse-detection to inform subsequent studies.</div></div><div><h3>Materials and Methods</h3><div>We applied a CE-certified qRT-PCR test to measure miR-371a-3p at each follow-up visit during active surveillance in 34 men with stage I testicular GCT. MiR-371a-3p levels were calculated by the ΔΔ method.</div></div><div><h3>Results</h3><div>About 18 Patients had pure seminoma and 16 had mixed or nonseminomatous testicular GCT. Recurrences were detected in 10 patients and were correctly identified by both raw and housekeeper-normalized miR-371a-3p serum levels. The raw Cq, with a cut-off value of &lt;28, resulted in only 1 false positive (3%), whereas RQ, with a cut-off value of &gt;15, produced 6 false positive results (17%). Most of these false positive results normalized in subsequent measurements. The RQ approach detected recurrence in 1 patient 6 months earlier than the raw Cq approach.</div></div><div><h3>Conclusion</h3><div>Our preliminary data suggest that this CE-certified assay, using previously suggested cut-off values, is a promising method for detecting disease recurrence, provided a confirmatory second test is conducted to identify false positive results. To avoid unnecessary scans or overtreatment, we are currently validating this assay and cut-offs in a prospective cohort study.</div></div>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":"42 12","pages":"Pages 455.e9-455.e13"},"PeriodicalIF":2.4000,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cut-offs for relapse detection in men with stage I testicular germ cell tumors during active surveillance within a prospective multicentre cohort study using either raw or housekeeper normalized miR-371a-3p serum levels\",\"authors\":\"Christian D. Fankhauser M.D. ,&nbsp;Marian S. Wettstein M.D., Ph.D. ,&nbsp;Ailsa J. Christiansen M.D., Ph.D. ,&nbsp;Christian Rothermundt M.D., PD ,&nbsp;Richard Cathomas M.D. ,&nbsp;Ernest Kaufmann M.D. ,&nbsp;Silvan Sigg M.D. ,&nbsp;Arnoud J. Templeton M.D. ,&nbsp;Anita Hirschi-Blickenstorfer M.D. ,&nbsp;Anja Lorch M.D. ,&nbsp;Silke Gillessen M.D. ,&nbsp;Joerg Beyer M.D. ,&nbsp;Thomas Hermanns M.D., PD\",\"doi\":\"10.1016/j.urolonc.2024.07.013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><div>MiR-371a-3p represents a novel liquid biomarker that detects all histologies of germ-cell tumors (GCT) except teratoma. However, it is currently unclear whether miR-371a-3p results obtained directly from RT-PCR (raw Cq) or normalized for housekeeper genes and transformed into the relative quantity (RQ) value should be used and at what cut-off level. The purpose of this research was to evaluate, which values should be used, and a potential cut-off level for relapse-detection to inform subsequent studies.</div></div><div><h3>Materials and Methods</h3><div>We applied a CE-certified qRT-PCR test to measure miR-371a-3p at each follow-up visit during active surveillance in 34 men with stage I testicular GCT. MiR-371a-3p levels were calculated by the ΔΔ method.</div></div><div><h3>Results</h3><div>About 18 Patients had pure seminoma and 16 had mixed or nonseminomatous testicular GCT. Recurrences were detected in 10 patients and were correctly identified by both raw and housekeeper-normalized miR-371a-3p serum levels. The raw Cq, with a cut-off value of &lt;28, resulted in only 1 false positive (3%), whereas RQ, with a cut-off value of &gt;15, produced 6 false positive results (17%). Most of these false positive results normalized in subsequent measurements. The RQ approach detected recurrence in 1 patient 6 months earlier than the raw Cq approach.</div></div><div><h3>Conclusion</h3><div>Our preliminary data suggest that this CE-certified assay, using previously suggested cut-off values, is a promising method for detecting disease recurrence, provided a confirmatory second test is conducted to identify false positive results. To avoid unnecessary scans or overtreatment, we are currently validating this assay and cut-offs in a prospective cohort study.</div></div>\",\"PeriodicalId\":23408,\"journal\":{\"name\":\"Urologic Oncology-seminars and Original Investigations\",\"volume\":\"42 12\",\"pages\":\"Pages 455.e9-455.e13\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Urologic Oncology-seminars and Original Investigations\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1078143924005660\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologic Oncology-seminars and Original Investigations","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1078143924005660","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:MiR-371a-3p 是一种新型液体生物标记物,可检测除畸胎瘤以外的所有组织形态的生殖细胞肿瘤 (GCT)。然而,目前还不清楚应该使用直接从 RT-PCR 中获得的 miR-371a-3p(原始 Cq)结果,还是将管家基因归一化后转换成相对量(RQ)值,以及使用何种临界值。本研究的目的是评估应使用哪些值以及复发检测的潜在临界值,为后续研究提供参考:我们在对 34 名睾丸 GCT I 期男性患者进行积极监测期间的每次随访时,采用经 CE 认证的 qRT-PCR 测试方法测量 miR-371a-3p。用ΔΔ法计算miR-371a-3p水平:结果:约18名患者为纯精原细胞瘤,16名患者为混合或非精原细胞瘤性睾丸GCT。10例患者检测到复发,原始和管家归一化的miR-371a-3p血清水平均能正确识别复发。原始 Cq 临界值为 15,产生了 6 个假阳性结果(17%)。这些假阳性结果大多在随后的测量中恢复正常。与原始 Cq 方法相比,RQ 方法提前 6 个月检测到 1 名患者的复发:我们的初步数据表明,这种经 CE 认证的检测方法采用了之前建议的临界值,是一种很有前途的检测疾病复发的方法,但前提是必须进行第二次确认性检测以识别假阳性结果。为了避免不必要的扫描或过度治疗,我们目前正在一项前瞻性队列研究中验证这种检测方法和临界值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Cut-offs for relapse detection in men with stage I testicular germ cell tumors during active surveillance within a prospective multicentre cohort study using either raw or housekeeper normalized miR-371a-3p serum levels

Purpose

MiR-371a-3p represents a novel liquid biomarker that detects all histologies of germ-cell tumors (GCT) except teratoma. However, it is currently unclear whether miR-371a-3p results obtained directly from RT-PCR (raw Cq) or normalized for housekeeper genes and transformed into the relative quantity (RQ) value should be used and at what cut-off level. The purpose of this research was to evaluate, which values should be used, and a potential cut-off level for relapse-detection to inform subsequent studies.

Materials and Methods

We applied a CE-certified qRT-PCR test to measure miR-371a-3p at each follow-up visit during active surveillance in 34 men with stage I testicular GCT. MiR-371a-3p levels were calculated by the ΔΔ method.

Results

About 18 Patients had pure seminoma and 16 had mixed or nonseminomatous testicular GCT. Recurrences were detected in 10 patients and were correctly identified by both raw and housekeeper-normalized miR-371a-3p serum levels. The raw Cq, with a cut-off value of <28, resulted in only 1 false positive (3%), whereas RQ, with a cut-off value of >15, produced 6 false positive results (17%). Most of these false positive results normalized in subsequent measurements. The RQ approach detected recurrence in 1 patient 6 months earlier than the raw Cq approach.

Conclusion

Our preliminary data suggest that this CE-certified assay, using previously suggested cut-off values, is a promising method for detecting disease recurrence, provided a confirmatory second test is conducted to identify false positive results. To avoid unnecessary scans or overtreatment, we are currently validating this assay and cut-offs in a prospective cohort study.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.80
自引率
3.70%
发文量
297
审稿时长
7.6 weeks
期刊介绍: Urologic Oncology: Seminars and Original Investigations is the official journal of the Society of Urologic Oncology. The journal publishes practical, timely, and relevant clinical and basic science research articles which address any aspect of urologic oncology. Each issue comprises original research, news and topics, survey articles providing short commentaries on other important articles in the urologic oncology literature, and reviews including an in-depth Seminar examining a specific clinical dilemma. The journal periodically publishes supplement issues devoted to areas of current interest to the urologic oncology community. Articles published are of interest to researchers and the clinicians involved in the practice of urologic oncology including urologists, oncologists, and radiologists.
期刊最新文献
Editorial Board Table of Contents Cover 2 - Masthead 2023 Star Reviewers for Urologic Oncology Cover 3 - Information for Authors
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1